Deterioration rate. Proportion of patients with Parkinson's disease with more than 30% increase in the total NHP score during the 4 year follow up period
| Patient characteristics in 1993 | Deterioration rate | % | p Value3-150 |
| Age (y): | |||
| <65 | 8/17 | 47.1 | |
| 65–75 | 38/67 | 56.7 | 0.276 |
| >75 | 19/27 | 70.4 | |
| Sex: | |||
| Male | 25/48 | 52.1 | |
| Female | 40/63 | 63.5 | 0.227 |
| UPDRS total score: | |||
| <20 | 9/20 | 45.0 | |
| 20–39 | 33/50 | 66.0 | |
| 40–59 | 20/29 | 69.0 | 0.023 |
| >60 | 3/12 | 25.0 | |
| Hoehn and Yahr stage: | |||
| 1 and 1.5 | 16/28 | 57.1 | |
| 2 and 2.5 | 32/51 | 62.7 | 0.275 |
| 3 | 13/20 | 65.0 | |
| 4 and 5 | 4/12 | 33.3 | |
| Duration of dopaminergic treatment (y): | |||
| <3 | 22/32 | 68.8 | |
| 3–10 | 32/57 | 56.1 | 0.338 |
| >10 | 11/22 | 50.0 | |
| Levodopa dose (mg/day): | |||
| <400 | 14/27 | 51.9 | |
| 400–700 | 39/61 | 63.9 | 0.391 |
| >700 | 11/22 | 50.0 | |
| MMSE score: | |||
| <24 | 4/12 | 33.3 | |
| ⩾24 | 61/99 | 61.6 | 0.071 |
| BDI score: | |||
| <18 | 53/87 | 60.9 | |
| ⩾18 | 11/21 | 52.4 | 0.475 |
↵3-150 Pearson χ2; Fisher's exact test when expected cell count<5.